Regenxbio Inc (NASDAQ:RGNX) price on current trading day, rose 8.97% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.50.
A look at the stock’s price movement, the close in the last trading session was $7.80, moving within a range at $7.9 and $9.06. The beta value (5-Year monthly) was 1.353. Turning to its 52-week performance, $23.14 and $5.62 were the 52-week high and 52-week low respectively. Overall, RGNX moved 12.14% over the past month.
Regenxbio Inc’s market cap currently stands at around $425.73 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-12.
Analysts have a consensus estimate of 105.39M for the company’s revenue for the quarter, with a low and high estimate of 20M and 132.4M respectively. The average forecast suggests up to a 574.65% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 325.24M, representing a 290.32% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RGNX is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend RGNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RGNX’s current price about 26.53% and 16.09% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 69.12, while 7-day volatility ratio is 13.77% and 8.40% in the 30-day chart. Further, Regenxbio Inc (RGNX) has a beta value of 1.21, and an average true range (ATR) of 0.64. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $18 and high of $30. Looking at the price targets, the low is -111.76% off current price level while to achieve the yearly target high, price needs to move -252.94%. Nonetheless, investors will most likely welcome a -158.82% jump to $22 which is the analysts’ median price.
If we refocus on Regenxbio Inc (NASDAQ:RGNX), historical trading data shows that trading volumes averaged 1.06 over the past 10 days and 1.17 million over the past 3 months. The company’s latest data on shares outstanding shows there are 49.55 million shares.
The 9.75% of Regenxbio Inc’s shares are in the hands of company insiders while institutional holders own 86.27% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.28 million on 2025-02-28, giving us a short ratio of 8.44. The data shows that as of 2025-02-28 short interest in Regenxbio Inc (RGNX) stood at 1658.0000000000002 of shares outstanding, with shares short falling to 6.41 million registered in 2025-01-31. Current price change has pushed the stock 9.96% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RGNX stock continues to rise going into the next quarter.
